Current therapies for Alzheimer’s disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.